Sperimentazione preclinica di radiofarmaci

  • A. Duatti
  • R. M. Moresco
  • S. Boschi
Chapter
Part of the Imaging & Formazione book series (IMAG)

Riassunto

Negli ultimi anni il rapido sviluppo delle biotecnologie ha permesso di acquisire importanti conoscenze sulle basi molecolari che regolano il funzionamento normale o patologico di organismi di diversa complessità. Dal punto di vista della medicina, ciò ha rappresentato la base per l’identificazione di approcci terapeutici innovativi fondati sul concetto di medicina molecolare e di terapia personalizzata. A loro volta, medicina molecolare e terapia personalizzata hanno determinato un notevole input e ampia diffusione delle metodiche di imaging biomedico sia in campo clinico sia, soprattutto negli ultimi anni, nel settore preclinico.

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografia

  1. 1.
    Pysz MA, Gambhir SS, Willmann JK (2010) Molecular imaging: current status and emerging strategies. Clin Radiol 65(7):500–516PubMedCrossRefGoogle Scholar
  2. 2.
    Pien HH, Fischman AJ, Thrall JH, Sorensen AG (2005) Using imaging biomarkers to accelerate drug development and clinical trials. Drug Discov Today 10:259–266PubMedCrossRefGoogle Scholar
  3. 3.
    Srinivas M, Aarntzen EH, Bulte JW et al (2010) Imaging of cellular therapies. Adv Drug Deliv Rev 62(11):1080–1093PubMedCrossRefGoogle Scholar
  4. 4.
    Hahn MA, Singh AK, Sharma P et al (2011) Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives. Anal Bioanal Chem 399(1):3–27PubMedCrossRefGoogle Scholar
  5. 5.
    Rice SL, Roney CA, Daumar P, Lewis JS (2011) The next generation of positron emission tomography radiopharmaceuticals in oncology. Semin Nucl Med 41(4):265–282PubMedCrossRefGoogle Scholar
  6. 6.
    Coenen HH, Elsinga PH, Iwata R et al (2010) Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences. Nucl Med Biol 37(7):727–740PubMedCrossRefGoogle Scholar
  7. 7.
    Chen K, Conti PS (2010) Target-specific delivery of peptide-based probes for PET imaging. Adv Drug Deliv Rev 62(11):1005–1022PubMedCrossRefGoogle Scholar
  8. 8.
    Harapanhalli RS (2010) Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals. Semin Nucl Med 40(5):364–384PubMedCrossRefGoogle Scholar
  9. 9.
    Ishiwata K, Kimura Y, Oda K et al (2010) Development of PET radiopharmaceuticals and their clinical applications at the Positron Medical Center. Geriatr Gerontol Int 10(Suppl 1):S180–S196PubMedGoogle Scholar
  10. 10.
    Dingemanse J, Appel-Dingemanse S (2007) Integrated pharmacokinetics and pharmacodynamics in drug development. Clin Pharmacokinet 46:713–737PubMedCrossRefGoogle Scholar
  11. 11.
    Pien HH, Fischman AJ, Thrall JH, Sorensen AG (2005) Using imaging biomarkers to accelerate drug development and clinical trials. Drug Discovery Today 10:259–266PubMedCrossRefGoogle Scholar
  12. 12.
    Takimoto CH, Wick M (2007) Preclinical drug development, in: AJ Atkinson, DR Abernethy, CE Daniels et al (eds) Principles of Clinical Pharmacology, 2nd edn. Academic Press, San DiegoGoogle Scholar
  13. 13.
    Singh SS (2007) Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab 7:165–182CrossRefGoogle Scholar
  14. 14.
    Korfmacher WA (2009) Advances in the integration of drug metabolism into the lead optimization paradigm. Mini Rev Med Chem 9:703–716PubMedCrossRefGoogle Scholar
  15. 15.
    National Centre for the Replacement, Refinement and Reduction of Animals in Research (2007) Challenging requirement for acute toxicity studies: A workshop report http://www.nc3rs.org.uk/downloaddoc.asp?id=559&page=22&skin=0Google Scholar
  16. 16.
    EMEA-CPMP (2009) ICH Topic M3 (R2) Non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals (CPMP/ICH/286/95) http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002720.pdfGoogle Scholar
  17. 17.
    Robinson S, Delongeas JL, Donald E et al (2008) A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development. Regul Toxicol Pharmacol 50:345–352PubMedCrossRefGoogle Scholar
  18. 18.
    Rudin M (2009) Noninvasive structural, functional, and molecular imaging in drug development. Curr Opinion Chem Biol 13:360–371CrossRefGoogle Scholar
  19. 19.
    Jain S, Dani P, Sharma RK (2009) Pharmacoscintigraphy: a blazing trail for the evaluation of new drugs and delivery systems. Crit Rev Ther Drug Carrier Syst 26:373–426PubMedCrossRefGoogle Scholar
  20. 20.
    Del Guerra A, Belcari N, Llacer GL et al (2008) Advanced radiation measurement techniques in diagnostic radiology and molecular imaging. Radiat Prot Dosimetry 131:136–142PubMedCrossRefGoogle Scholar
  21. 21.
    Kang JH, Chung JK (2008) Molecular-genetic imaging based on reporter gene expression. J Nucl Med 49(Suppl 2):164S–179SPubMedCrossRefGoogle Scholar
  22. 22.
    Sauter AW, Wehrl HF, Kolb A et al (2010) Combined PET/MRI: one step further in multimodality imaging. Trends Mol Med 16(11):508–515PubMedCrossRefGoogle Scholar
  23. 23.
    Rowland DJ, Cherry SR (2008) Small-animal preclinical nuclear medicine instrumentation and methodology. Semin Nucl Med 38(3):209–222PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2013

Authors and Affiliations

  • A. Duatti
  • R. M. Moresco
  • S. Boschi

There are no affiliations available

Personalised recommendations